Initial Results of the Ongoing MYSTIC Trial in Stage IV Lung Cancer
David R. Gandara, MD, professor of Medicine, University of California Davis Comprehensive Cancer Center, discusses the initial results of the ongoing MYSTIC trial, which is exploring the combination of durvalumab (Imfinzi) and tremelimumab versus chemotherapy in stage IV lung cancer.
David R. Gandara, MD, professor of Medicine, University of California Davis Comprehensive Cancer Center, discusses the initial results of the ongoing MYSTIC trial, which is exploring the combination of durvalumab (Imfinzi) and tremelimumab versus chemotherapy in stage IV lung cancer.
Related Videos
Related Content
